Form 4: C4 Therapeutics CFO Kendra Adams Reports Stock Transactions

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reports acquisition and disposal of company stock and stock options.

Summary

• On February 13, 2025, C4 Therapeutics CFO Kendra Adams had 1,863 shares withheld to cover tax obligations at a price of $3.2.
• On February 14, 2025, Adams acquired 87,100 shares of common stock in the form of Restricted Stock Units (RSUs) at $0.
• These RSUs vest in four equal annual installments starting February 14, 2026.
• Also on February 14, 2025, 4,559 shares were withheld for taxes at $3.18.
• Adams also acquired options to buy 130,600 shares at $3.18, vesting monthly starting March 14, 2025, and expiring on February 13, 2035.
• Following these transactions, Adams directly owns 165,117 shares of C4 Therapeutics common stock and options to buy 130,600 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions related to executive compensation. The acquisition of shares and options could be seen as a positive, but it's a routine part of executive compensation.

Positives

• The acquisition of RSUs by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The reported transactions reflect ongoing compensation and incentive plans for the company's executives, with RSUs vesting over time and stock options providing the right to purchase shares in the future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules for RSUs and stock options typically range from three to five years, which is consistent with the vesting terms reported in this filing.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders by increasing the number of shares potentially available in the market as options vest and are exercised.
• Employees may be impacted positively as the CFO's incentives are further aligned with the company's success.

Key Dates

Keywords

C4 Therapeutics, Kendra Adams, CFO, Form 4, Stock Options, RSUs, Share Acquisition, Share Disposal, Beneficial Ownership